EMEA-001350-PIP02-13-M04
Key facts
Invented name |
Zydelig
|
Active substance |
Idelalisib
|
Therapeutic area |
Oncology
|
Decision number |
P/0345/2018
|
PIP number |
EMEA-001350-PIP02-13-M04
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of mature B-cell neoplasms
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Gilead Sciences International Limited
Tel. +44 (0)1223 897300 |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|